Όλο το DSpace

Πλοήγηση ανά Θέμα "hepatitis B surface antigen"

Αποτελέσματα 1-18 από 18

    • Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient 

      Eleftheriadis T., Pissas G., Liakopoulos V., Stefanidis I. (2021)
      Immune checkpoint inhibitors by blocking specific inhibitory pathways induce T-cell-mediated tumor lysis. However, many remain to be elucidated about their effect on human humoral immunity. We evaluated the effect of the ...

    • Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome 

      Keskin O., Wedemeyer H., Tüzün A., Zachou K., Deda X., Dalekos G.N., Heidrich B., Pehlivan S., Zeuzem S., Yalçin K., Gürel S., Tabak F., Idilman R., Bozkaya H., Manns M., Yurdaydin C. (2015)
      Background & Aims: Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection. No rules have been set for stopping treatment based on viral kinetics. We analyzed data from an international ...

    • Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN) 

      Wranke A., Pinheiro Borzacov L.M., Parana R., Lobato C., Hamid S., Ceausu E., Dalekos G.N., Rizzetto M., Turcanu A., Niro G.A., Lubna F., Abbas M., Ingiliz P., Buti M., Ferenci P., Vanwolleghem T., Hayden T., Dashdorj N., Motoc A., Cornberg M., Abbas Z., Yurdaydin C., Manns M.P., Wedemeyer H., Hardtke S., Serrano B., Wöbse M., Heidrich B., Muche M., Gatselis N., Zachou K., Ho E., Smedile A., Fontana R., Gish R., Obretin D., Stern R., the Hepatitis Delta International Network (2018)
      Background & Aims: Chronic hepatitis D (delta) is a major global health burden. Clinical and virological characteristics of patients with hepatitis D virus (HDV) infection and treatment approaches in different regions ...

    • Cryoglobulinemia due to chronic viral hepatitis infections is not a major problem in clinical practice 

      Christodoulou, D. K.; Dalekos, G. N.; Merkouropoulos, M. H.; Kistis, K. G.; Georgitsi, G.; Zervou, E.; Zachou, K.; Tsianos, E. V. (2001)
      Background: Essential mixed cryoglobulinemia (EMC) is a systemic disease frequently associated with chronic viral hepatitis. This study was conducted in order to assess the prevalence of EMC in patients with hepatitis B ...

    • Daring-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B 

      Papatheodoridis G.V., Rigopoulou E.I., Papatheodoridi M., Zachou K., Xourafas V., Gatselis N., Hadziyannis E., Vlachogiannakos J., Manolakopoulos S., Dalekos G.N. (2018)
      Background: The remission rates after stopping antivirals in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) vary among studies, while reliable predictors of relapse have not been identified. This prospective ...

    • HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response 

      Niro G.A., Smedile A., Fontana R., Olivero A., Ciancio A., Valvano M.R., Pittaluga F., Coppola N., Wedemeyer H., Zachou K., Marrone A., Fasano M., Lotti G., Andreone P., Iacobellis A., Andriulli A., Rizzetto M. (2016)
      Background: Therapy of chronic hepatitis D with Interferon is successful when testing for HDV-RNA turns negative. This end-point is disputed. Aim: To assess the role of serum hepatitis B surface antigen (HBsAg) in the ...

    • Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B 

      Papatheodoridis G.V., Sypsa V., Dalekos G.N., Yurdaydin C., Van Boemmel F., Buti M., Calleja J.L., Chi H., Goulis J., Manolakopoulos S., Loglio A., Voulgaris T., Gatselis N., Keskin O., Veelken R., Lopez-Gomez M., Hansen B.E., Savvidou S., Kourikou A., Vlachogiannakos J., Galanis K., Idilman R., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2020)
      Background & Aims: Hepatocellular carcinoma (HCC) may develop in patients with chronic hepatitis (CHB) even after 5 years of oral therapy and cannot be easily predicted. We assessed predictors of HCC development and the ...

    • Intrafamilial spread of hepatitis B virus infection in Greece 

      Zervou, E. K.; Gatselis, N. K.; Xanthi, E.; Ziciadis, K.; Georgiadou, S. P.; Dalekos, G. N. (2005)
      Objective: No study has investigated the intrafamilial spread of hepatitis B virus (HBV) in Greece. We conducted a 9-year prospective study to determine the rate of HBV spread in family members when a member is identified ...

    • Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta 

      Heidrich, B.; Yurdaydin, C.; Kabaçam, G.; Ratsch, B. A.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Tabak, F.; Yalcin, K.; Gürel, S.; Zeuzem, S.; Cornberg, M.; Bock, C. T.; Manns, M. P.; Wedemeyer, H. (2014)
      Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ...

    • Markers of hepatitis viruses and human T-lymphotropic virus types I/II in patients who have undergone open-heart surgery: Evidence of increased risk for exposure to HBV and HEV 

      Zervou, E. K.; Georgiadou, S. P.; Liapi, G. K.; Karabini, F.; Giogiakas, V.; Zisiadis, K.; Gatselis, N. K.; Goudevenos, I.; Dalekos, G. N. (2005)
      Background: Open-heart procedure is characterized by a high-risk for contracting blood-borne infections. We evaluated the prevalence of several markers of hepatitis viruses (B-E) and human T-cell lymphotropic virus types ...

    • Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B 

      Papatheodoridi M., Hadziyannis E., Berby F., Zachou K., Testoni B., Rigopoulou E., Gatselis N.K., Lyberopoulou A., Vlachogiannakos I., Manolakopoulos S., Dalekos G.N., Zoulim F., Papatheodoridis G.V. (2020)
      Reliable predictors of outcomes after treatment discontinuation in HBeAg-negative chronic hepatitis B (CHB) patients have not been established. We investigated the role of hepatitis B surface antigen (HBsAg), interferon-inducible ...

    • Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis 

      Zachou, K.; Yurdaydin, C.; Drebber, U.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Bozkaya, H.; Schlaphoff, V.; Dienes, H. P.; Bock, T. C.; Manns, M. P.; Wedemeyer, H. (2010)
      Background: Hepatitis delta virus (HDV) causes severe liver disease. Aims: To investigate the quantitative HDV-RNA, HBsAg and hepatitis B virus (HBV)DNA levels in correlation to histological, biochemical and demographical ...

    • The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B 

      Papatheodoridis G.V., Idilman R., Dalekos G.N., Buti M., Chi H., van Boemmel F., Calleja J.L., Sypsa V., Goulis J., Manolakopoulos S., Loglio A., Siakavellas S., Keskın O., Gatselis N., Hansen B.E., Lehretz M., de la Revilla J., Savvidou S., Kourikou A., Vlachogiannakos I., Galanis K., Yurdaydin C., Berg T., Colombo M., Esteban R., Janssen H.L.A., Lampertico P. (2017)
      Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy with potent nucleos(t)ide analogues is currently unclear. We therefore assessed the HCC incidence ...

    • Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta 

      Kabaçam, G.; Wedemeyer, H.; Savaş, B.; Keskin, O.; Dalekos, G.; Tabak, F.; Idilman, R.; Erhardt, A.; Yalçin, K.; Bozdayi, M. A.; Bozkaya, H.; Manns, M.; Dienes, H.; Yurdaydin, C.; Berg, T.; Böcher, W.; Bohle, H.; Buggisch, P.; Cornberg, M.; Ers̈oz, G.; Feyerabend, S.; Hinrichsen, H.; Manok, M.; Häussinger, D.; Herzog, W.; Hofmann, W. P.; Plein, K.; Hardt, H.; Porst, H.; Mederacke, I.; Rigopoulou, E. I.; Sentürk, H.; Wagner, E. K. V. (2014)
      Background & Aims: Immunohistochemical assessment of liver tissue in chronic delta hepatitis (CDH) is underinvestigated. Aim of the study was (i) to assess variables associated with hepatitis D antigen (HDAg), hepatitis B ...

    • Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy 

      Papatheodoridi M., Papachristou E., Moschidis Z., Hadziyannis E., Rigopoulou E., Zachou K., Villeret F., Magiorkinis G., Lyberopoulou A., Gatselis N., Vlachogiannakos I., Manolakopoulos S., Dalekos G.N., Zoulim F., Paraskevis D., Papatheodoridis G.V. (2022)
      HBV RNA is considered as a promising predictor in patients who discontinue nucleos(t)ide analogues (NAs). We determined HBV RNA levels in non-cirrhotic HBeAg-negative patients who discontinued NAs and assessed their ...

    • Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B 

      Papatheodoridis G.V., Dalekos G.N., Idilman R., Sypsa V., Van Boemmel F., Buti M., Calleja J.L., Goulis J., Manolakopoulos S., Loglio A., Papatheodoridi M., Gatselis N., Veelken R., Lopez-Gomez M., Hansen B.E., Savvidou S., Kourikou A., Vlachogiannakos J., Galanis K., Yurdaydin C., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2020)
      Background & Aims: A recent study in Asian patients with chronic hepatitis B (CHB) reported that the incidence of hepatocellular carcinoma (HCC) was lower in patients treated with tenofovir disoproxil fumarate (TDF) than ...

    • The state of hepatitis B and C in the mediterranean and balkan countries: Report from a summit conference 

      Hatzakis, A.; Van Damme, P.; Alcorn, K.; Gore, C.; Benazzouz, M.; Berkane, S.; Buti, M.; Carballo, M.; Cortes Martins, H.; Deuffic-Burban, S.; Dominguez, A.; Donoghoe, M.; Elzouki, A. N.; Ben-Alaya Bouafif, N.; Esmat, G.; Esteban, R.; Fabri, M.; Fenton, K.; Goldberg, D.; Goulis, I.; Hadjichristodoulou, T.; Hatzigeorgiou, T.; Hamouda, O.; Hasurdjiev, S.; Hughes, S.; Kautz, A.; Malik, M.; Manolakopoulos, S.; Matičič, M.; Papatheodoridis, G.; Peck, R.; Peterle, A.; Potamitis, G.; Prati, D.; Roudot-Thoraval, F.; Reic, T.; Sharara, A.; Shennak, M.; Shiha, G.; Shouval, D.; Sočan, M.; Thomas, H.; Thursz, M.; Tosti, M.; Trépo, C.; Vince, A.; Vounou, E.; Wiessing, L.; Manns, M. (2013)
      The burden of disease due to chronic viral hepatitis constitutes a global threat. In many Balkan and Mediterranean countries, the disease burden due to viral hepatitis remains largely unrecognized, including in high-risk ...

    • Tuberculous pyomyositis: A re-emerging entity of many faces 

      Simopoulou T., Varna A., Dailiana Z., Katsiari C., Alexiou I., Basdekis G., Malizos K.N., Sakkas L.I. (2016)
      Tuberculosis (TB) has become a global concern due to its increasing incidence, particularly in immunocompromised patients, closely following the migratory patterns of populations. TB pyomyositis is a rare extrapulmonary ...